NASDAQ:PMVP PMV Pharmaceuticals Q3 2025 Earnings Results & Report $1.21 -0.08 (-6.20%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$1.22 +0.01 (+0.41%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. PMV Pharmaceuticals met analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.40 versus the -$0.40 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market OpensConference Call8:00 AM ET PMV Pharmaceuticals EPS ResultsActual EPS-$0.40Consensus EPS -$0.40Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersPMV Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsPMV Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) PMV Pharmaceuticals Q3 2025 Earnings FAQ Did PMV Pharmaceuticals beat earnings estimates for Q3 2025? PMV Pharmaceuticals (NASDAQ:PMVP) reported earnings of -$0.40 per share for Q3 2025, matching the consensus estimate of -$0.40. The report was announced on Wednesday, November 12, 2025. When is PMV Pharmaceuticals' next earnings date? PMV Pharmaceuticals' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for PMV Pharmaceuticals on the company's earnings history page. PMV Pharmaceuticals Earnings HeadlinesPMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer OpportunityOctober 7, 2026 | seekingalpha.comPMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of DirectorsOctober 5, 2026 | finance.yahoo.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), PMV Pharmaceuticals (PMVP) and Tyra Bioscience (TYRA)September 9, 2026 | theglobeandmail.comPMV Pharma Names Herman Chief Commercial Officer Ahead Of Rezatapopt FilingSeptember 9, 2026 | rttnews.comPMV Pharmaceuticals Appoints Philip Herman as Chief Commercial OfficerSeptember 8, 2026 | finance.yahoo.comSee More PMV Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email. Email Address About PMV PharmaceuticalsPMV Pharmaceuticals (NASDAQ:PMVP) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research centers on p53, a tumor-suppressor protein that is frequently altered in cancer, with the goal of developing therapies that restore the protein’s function in tumors containing specific p53 mutations. PMV’s lead investigational product is rezatapopt (also known as PC14586), an orally administered small-molecule therapy designed to selectively reactivate the Y220C mutation of p53. The company has evaluated rezatapopt in clinical studies involving patients with advanced solid tumors harboring this mutation. As a development-stage biotechnology company, PMV’s activities have primarily involved drug discovery, clinical research and development rather than the sale of marketed products. Founded in 2013, PMV Pharmaceuticals is headquartered in Cranbury, New Jersey. Its research and clinical-development programs are directed toward patients with genetically defined cancers, with clinical studies conducted through participating sites in relevant geographies. The company’s common stock trades on the Nasdaq Capital Market under the symbol PMVP.View PMV Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
